Search

Your search keyword '"Locatelli, Silvia Laura"' showing total 7 results
Start Over Author "Locatelli, Silvia Laura" Journal blood
7 results on '"Locatelli, Silvia Laura"'

1. Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma

Author

Spina, Valeria, Bruscaggin, Alessio, Cuccaro, Annarosa, Martini, Maurizio, Di Trani, Martina, Forestieri, Gabriela, Manzoni, Martina, Condoluci, Adalgisa, Arribas, Alberto, Terzi-Di-Bergamo, Lodovico, Locatelli, Silvia Laura, Cupelli, Elisa, Ceriani, Luca, Moccia, Alden A., Stathis, Anastasios, Nassi, Luca, Deambrogi, Clara, Diop, Fary, Guidetti, Francesca, Cocomazzi, Alessandra, Annunziata, Salvatore, Rufini, Vittoria, Giordano, Alessandro, Neri, Antonino, Boldorini, Renzo, Gerber, Bernhard, Bertoni, Francesco, Ghielmini, Michele, Stüssi, Georg, Santoro, Armando, Cavalli, Franco, Zucca, Emanuele, Larocca, Luigi Maria, Gaidano, Gianluca, Hohaus, Stefan, Carlo-Stella, Carmelo, and Rossi, Davide

Published
2018
Full Text
View/download PDF

2. Treatment of Hodgkin Lymphoma Xenografts with the Novel PI3K δ/γ Inhibitor RP6530 Suppresses M2 Macrophage Polarization and Results in Potent Antitumor and Antiangiogenic Effects

Author

Locatelli, Silvia Laura, primary, Consonni, Francesca Maria, additional, Careddu, Giuseppa, additional, Serio, Simone, additional, Viswanadha, Srikant, additional, Vakkalanka, Swaroop, additional, Castagna, Luca, additional, Santoro, Armando, additional, and Carlo-Stella, Carmelo, additional

Published
2016
Full Text
View/download PDF

3. Clinical Activity and Safety of RP6530, a Dual PI3Kδ/γ Inhibitor, in Patients with Advanced Hematologic Malignancies: Final Analysis of a Phase 1 Multicenter Study

Author

Carlo-Stella, Carmelo, primary, Delarue, Richard, additional, Barde, Prajak J, additional, Scarfo, Lydia, additional, Kumar, Uday, additional, Viswanadha, Srikant, additional, Locatelli, Silvia Laura, additional, Gandolfi, Sara, additional, Pittari, Valeria, additional, Morello, Lucia, additional, Magagnoli, Massimo, additional, Santoro, Armando, additional, and Ferreri, Andrés J.M., additional

Published
2016
Full Text
View/download PDF

4. A Dose Escalation Study of RP6530, a Novel Dual PI3K Delta/Gamma Inhibitor, in Patients with Relapsed/Refractory Hematologic Malignancies

Author

Carlo-Stella, Carmelo, primary, Delarue, Richard, additional, Barde, Prajak J, additional, Scarfo, Lydia, additional, Saheb, Thamila, additional, Kumar, Uday, additional, Viswanadha, Srikant, additional, Gandolfi, Sara, additional, Pittari, Valeria, additional, Santoro, Armando, additional, Locatelli, Silvia Laura, additional, Vakkalanka, Swaroop, additional, Ghia, Paolo, additional, and Ferreri, Andres J.M., additional

Published
2015
Full Text
View/download PDF

7. The Novel Calcium Release-Activated Calcium (CRAC) Channel Inhibitor RP4010 Exerts Potent Antitumor Effects in NOD/SCID/IL2Rg-/-Mice with Diffuse Large B Cell Lymphoma (DLBCL) Cell Line Xenografts

Author

Locatelli, Silvia Laura, Careddu, Giuseppa, Magagnoli, Massimo, di Trani, Martina, Morello, Lucia, Viswanadha, Srikant, Vakkalanka, Swaroop Kumar VS, Castagna, Luca, Santoro, Armando, and Carlo-Stella, Carmelo

Abstract

INTRODUCTION:Calcium ions (Ca2+) act as second messengers in cell signaling triggering various cellular processes, including gene transcription, secretion, cell proliferation, migration, and apoptosis. Store-operated Ca2+entry (SOCE) is activated by Ca2+release from the endoplasmic reticulum. Two genes are responsible for SOCE activity: Stromal interaction molecule 1 (STIM1), an ER Ca2+sensor that detects store depletion and Orai1, the pore-forming subunit of Ca2+release-activated Ca2+(CRAC) channel. Downregulation of Orai1, and consequently SOCE, protects the cells from diverse apoptosis-inducing pathways. As emerging evidence points to the involvement of aberrant CRAC channel activity in human diseases including Diffuse Large B Cell Lymphoma (DLBCL), we hypothesize that the CRAC channel inhibitorRP4010 might represent a unique therapeutic opportunity for DLBCL patients. RP4010 is a potent inhibitor of CRAC channel activity (IC50=60 nM) with demonstrated efficacy across a range of cancer cell lines in vitro. This study aimed at investigating the activity of RP4010 in preclinical DLBCL models.

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results